Stay updated on XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Sign up to get notified when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.

Latest updates to the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe record describes a Phase 1b trial of XMT-1592 for ovarian cancer and non-small cell lung cancer, including study eligibility, treatment arms, and outcome measures. It indicates the study was terminated because the development program was discontinued and is no longer recruiting.SummaryDifference44%

- Check16 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the study record page continues to show a 403 Forbidden error rather than trial details.SummaryDifference0.2%

- Check30 days agoChange DetectedA notice about NIH websites and terminology appears above the ClinicalTrials.gov 403 error page. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check37 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the detailed record. The trial information and navigation are no longer accessible, leaving only the site header and error message.SummaryDifference18%

Stay in the know with updates to XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.